Genfit SA represents several core values and a strong corporate philosophy. The company prioritizes innovation and strives to develop groundbreaking solutions in the field of liver and metabolic diseases. Genfit SA is committed to patient-centric research and aims to improve the lives of individuals suffering from these ailments. With a focus on scientific excellence and commitment to ethical practices, Genfit SA believes in fostering collaborations and partnerships to drive progress. By combining cutting-edge research and a patient-oriented approach, Genfit SA aims to become a leading global biopharmaceutical company in its targeted therapeutic areas.

Genfit SA is primarily present in various countries and regions. The company operates not only in its home country, France, but also has a significant presence in the United States. Genfit SA also has a growing presence in other parts of the world, including Europe and Asia. This global expansion allows the company to reach a wider market and tap into diverse patient populations. With its increasing footprint, Genfit SA is well-positioned to cater to the needs of patients and healthcare providers in different countries and regions, driving its growth and success.

Genfit SA, a leading biopharmaceutical company, has achieved numerous significant milestones. Notably, the company successfully completed Phase 3 clinical trials for its investigational drug, elafibranor, in patients with nonalcoholic steatohepatitis (NASH). This milestone is remarkable as it demonstrated the drug's potential in treating a widespread liver disease with no approved therapies. Genfit SA also received Breakthrough Therapy designation from the FDA, highlighting the drug's promising efficacy and safety profile. Moreover, the company has established strong collaborations, such as the strategic alliance with LabCorp, to advance the diagnosis and treatment of NASH. Genfit SA continues to forge ahead in its mission to address significant unmet medical needs and improve patient outcomes.

Genfit SA is a renowned biopharmaceutical company based in France. Established in 1999, Genfit specializes in the development of innovative therapeutic and diagnostic solutions to address metabolic, inflammatory, and liver diseases. With a strong focus on pioneering research and advanced clinical trials, Genfit has positioned itself as a leading player in the pharmaceutical industry. The company's primary mission is to improve patient outcomes by combating diseases that represent significant medical and social challenges. Genfit SA continually strives to create value for its stakeholders through its commitment to scientific excellence, strategic collaborations, and dedication to addressing unmet medical needs.

The main competitors of Genfit SA in the market are Intercept Pharmaceuticals, Inc., Viking Therapeutics, Inc., and Madrigal Pharmaceuticals, Inc.

Genfit SA is primarily active in the pharmaceutical and biotechnology industries.

Genfit SA's business model focuses on developing and commercializing innovative therapeutic solutions for patients with metabolic and liver-related diseases. The company primarily specializes in non-alcoholic steatohepatitis (NASH), which is a progressive disease of the liver. Genfit SA's business strategy involves conducting research and development activities, clinical trials, and obtaining regulatory approvals. By creating a pipeline of potential drug candidates, Genfit SA aims to address the unmet medical needs of individuals suffering from NASH and related conditions. The company's ultimate goal is to provide effective treatment options and improve the overall quality of life for patients in this specific market.

The Genfit P/E ratio is 8.31.

The Genfit P/S ratio is 2.13.

The Quality Investing for Genfit is 5/10.

The expected Genfit revenue is 88.08 M EUR.

The expected Genfit profit is 22.55 M EUR.

Genfit SA is a French biotech company focused on the development and commercialization of therapies for the treatment of metabolic diseases. The company is listed on the Euronext stock exchange in Paris and also has a branch in the US. Genfit SA utilizes an integrated business model that focuses on three main activities: research and development, diagnostics, and therapeutics.

Genfit pays a dividend of 0 EUR distributed over payouts per year.

The dividend cannot currently be calculated for Genfit or the company does not pay out a dividend.

The ISIN of Genfit is FR0004163111.

The WKN of Genfit is A0LGJ2.

The ticker of Genfit is GNFT.PA.

Over the past 12 months, Genfit paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Genfit is expected to pay a dividend of 0 EUR.

The current dividend yield of Genfit is .

Genfit pays a quarterly dividend. This is distributed in the months of .

Genfit paid dividends every year for the past 0 years.

For the upcoming 12 months, dividends amounting to 0 EUR are expected. This corresponds to a dividend yield of 0 %.

Genfit is assigned to the 'Health' sector.

To receive the latest dividend of Genfit from 12/3/2024 amounting to 0 EUR, you needed to have the stock in your portfolio before the ex-date on 12/3/2024.

The last dividend was paid out on 12/3/2024.

In the year 2023, Genfit distributed 0 EUR as dividends.

The dividends of Genfit are distributed in EUR.